Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/26
WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?Zacks Investment Research • 12/11/25
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewsWire • 12/10/25
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewsWire • 12/08/25
Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity TranscriptSeeking Alpha • 12/08/25
Wave Life Sciences surges after early data shows fat loss benefits from experimental obesity drugProactive Investors • 12/08/25
Wave Life Sciences Just Targeted Fat Loss, Specifically. Shares Skyrocketed 80%.Investors Business Daily • 12/08/25
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle LossGlobeNewsWire • 12/08/25
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025GlobeNewsWire • 12/07/25
Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/10/25
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/10/25
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025GlobeNewsWire • 11/05/25
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025GlobeNewsWire • 11/04/25
Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics TranscriptSeeking Alpha • 11/01/25
Wave Life Sciences (WVE) Soars 8.8%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/30/25